This means that drug sponsors like Novartis, Amgen, and Mylan looking to break into the biosimilars market will have to stick with the status quo (for now).http://on.bna.com/slei30kCI9a
0 replies
2 retweets
1 like
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
Follow our journalists: